NovaBridge Biosciences (NBP) Net Income (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Net Income of $72.9 million for Q4 2025, up 571.87% year-over-year from $10.8 million in Q4 2024, and up 967.05% quarter-over-quarter from $6.8 million in Q3 2025.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Net Income (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Net Income for 5 consecutive years, with $72.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Income rose 571.87% year-over-year to $72.9 million; the TTM figure through Dec 2025 stood at $71.0 million (up 1040.89% YoY), while the FY2025 annual figure was $88.3 million, up 297.39% from the prior year.
- Net Income improved to $72.9 million in Q4 2025 per NBP's latest filing, from $6.8 million in the prior quarter.
- Across five years, Net Income topped out at $72.9 million in Q4 2025 and bottomed at -$25.0 million in Q3 2023.
- Historically, Net Income has averaged $5.8 million across 3 years, with a median of $0.18 in 2024.
- On a YoY basis, Net Income climbed as much as 571.87% in 2025 and fell as far as 3057777877.78% in 2025.
- NovaBridge Biosciences' Net Income stood at -$25.0 million in 2023, then soared by 143.32% to $10.8 million in 2024, then jumped by 571.87% to $72.9 million in 2025.
- Business Quant data shows NBP's Net Income at $72.9 million in Q4 2025, $6.8 million in Q3 2025, and -$5.5 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 10 | NovaBridge Biosciences | 199.33 Mn | 199.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 72.86 Mn |
| Sep 30, 2025 | 6.83 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | 10.84 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | -8.94 Mn |
| Mar 31, 2024 | -16.32 Mn |
| Dec 31, 2023 | -162.42 Mn |
| Sep 30, 2023 | -8.22 Mn |
| Jun 30, 2023 | -27.56 Mn |
| Dec 31, 2020 | -15.05 Mn |
| Sep 30, 2020 | 166.65 Mn |
| Dec 31, 2019 | 49.46 Mn |
| Sep 30, 2019 | -35.10 Mn |